
Automation, decentralization and the future of CAR-Ts: Advancements in cell & gene therapy manufacturing (Part III)
The Top Line
Risks and Uncertainties in CAR-T Treatment: Secondary T-cell Malignancies
Exploring the FDA's findings on T-cell cancers after CAR-T therapy, focusing on the correlation and call for further investigation into the relationship between CAR-T treatment and secondary malignancies.
00:00
Transcript
Play full episode
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.